To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D
Voluntary participation in this study, signed informed consent, compliance is good, can cooperate with follow-up
Age 18-80 years old (including both ends), both male and female
Subjects with advanced or metastatic malignant tumors confirmed by pathological tissue or cytology, and who have failed previous standard treatments, are intolerant to standard treatments, or have no standard treatments
Have measurable lesions
Central nervous system metastasis or meningeal metastasis with clinical symptoms
Spinal cord compression that has not been treated radically by surgery and/or radiotherapy
Patients with uncontrolled tumor-related pain as judged by the investigator
A third space effusion with uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion, as determined by the investigator